Federated Hermes Inc. Sells 169,473 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Federated Hermes Inc. reduced its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 4.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,272,761 shares of the company’s stock after selling 169,473 shares during the quarter. Federated Hermes Inc. owned approximately 0.07% of Amphastar Pharmaceuticals worth $202,420,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in AMPH. Price T Rowe Associates Inc. MD raised its holdings in Amphastar Pharmaceuticals by 396.7% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 808,731 shares of the company’s stock worth $22,727,000 after purchasing an additional 645,917 shares in the last quarter. Bank of America Corp DE raised its holdings in Amphastar Pharmaceuticals by 347.2% in the 1st quarter. Bank of America Corp DE now owns 290,737 shares of the company’s stock worth $10,903,000 after purchasing an additional 225,728 shares in the last quarter. State Street Corp raised its holdings in Amphastar Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 1,540,846 shares of the company’s stock worth $53,606,000 after purchasing an additional 218,895 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Amphastar Pharmaceuticals by 183.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 329,843 shares of the company’s stock worth $11,475,000 after buying an additional 213,355 shares during the period. Finally, Penserra Capital Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter worth about $6,418,000. 65.09% of the stock is currently owned by institutional investors.

Insider Transactions at Amphastar Pharmaceuticals

In other news, Director Michael A. Zasloff sold 12,500 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the transaction, the director now owns 21,326 shares in the company, valued at approximately $1,006,160.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the sale, the director now owns 80,333 shares in the company, valued at approximately $4,265,682.30. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Michael A. Zasloff sold 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total transaction of $589,750.00. Following the sale, the director now owns 21,326 shares in the company, valued at approximately $1,006,160.68. The disclosure for this sale can be found here. Insiders have sold 14,000 shares of company stock worth $660,860 in the last quarter. Company insiders own 28.40% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on AMPH shares. JPMorgan Chase & Co. started coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, April 10th. Finally, StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $66.00.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH traded down $0.59 during trading on Thursday, reaching $39.46. 71,963 shares of the company traded hands, compared to its average volume of 460,936. The firm has a 50 day simple moving average of $46.59 and a 200-day simple moving average of $51.23. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $1.93 billion, a PE ratio of 15.52, a P/E/G ratio of 0.98 and a beta of 0.84. Amphastar Pharmaceuticals, Inc. has a 52-week low of $35.62 and a 52-week high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. The business had revenue of $178.11 million during the quarter, compared to the consensus estimate of $174.90 million. Equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.42 earnings per share for the current year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.